scholarly journals Caution against injudicious vaccine allergy skin tests: Adverse reactions after intradermal COVID‐19 vaccine testing

2021 ◽  
Author(s):  
Valerie Chiang ◽  
Pearl P. T. Mong ◽  
Edward K. K. Chan ◽  
Elaine Y. L. Au ◽  
Philip H. Li
Keyword(s):  
Adverse Reactions ◽  
Skin Tests ◽  
Vaccine Testing

scholarly journals Skin tests in adverse reactions to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of intradermal testing

2021 ◽  
Author(s):  
Leonardo Bianchi ◽  
Filippo Biondi ◽  
Katharina Hansel ◽  
Nicola Murgia ◽  
Marta Tramontana ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Skin Tests ◽  
Intradermal Testing

scholarly journals Comment on caution against injudicious vaccine allergy skin test and adverse reactions after intradermal COVID ‐19 vaccine testing

2021 ◽  
Author(s):  
Leonardo Bianchi ◽  
Katharina Hansel ◽  
Filippo Biondi ◽  
Nicola Murgia ◽  
Marta Tramontana ◽  
...  
Keyword(s):  
Skin Test ◽  
Adverse Reactions ◽  
Vaccine Testing

scholarly journals Skin tests with SARS-CoV2 vaccine excipients in patients with first-dose mucous-cutaneous adverse reactions: a purpose of allergologic workup

2021 ◽  
Author(s):  
Leonardo Bianchi ◽  
Filippo Biondi ◽  
Katharina Hansel ◽  
Nicola Murgia ◽  
Alessandro D’Arpino ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Skin Tests ◽  
Cutaneous Adverse Reactions

scholarly journals Drug reexposure in children with severe mucocutaneous reactions

2022 ◽  
Vol 50 (1) ◽  
pp. 104-107
Author(s):  
Luis Moral ◽  
Teresa Toral ◽  
Ana Gilabert ◽  
Ares Sánchez ◽  
Juan Francisco Silvestre ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Provocation Test ◽  
Skin Tests ◽  
In Vitro Tests ◽  
Severe Reaction ◽  
Pediatric Allergy ◽  
Drug Provocation Test ◽  
History Of ◽  
Cutaneous Adverse Reactions

In pediatric patients, severe cutaneous adverse reactions (SCARs) frequently occur in the course of acute illnesses, mostly infections, which are usually treated with antibiotics or analgesics. The drug provocation test (DPT) is contraindicated in such situations, due to the risk of triggering a new severe reaction. As a consequence, lifelong avoidance is recommended. However, causation is uncertain in most cases. The dilemma arises when avoiding the drug is not harmless for the patient. We have attended three patients who were referred to our pediatric allergy unit with a history of SCAR related in time to simultaneous use of paracetamol and ibuprofen. Medical records and images of the patients were reviewed with the assistance of a dermatologist, and alternative diagnoses were considered in both cases. The ALDEN score for implicated drugs was calculated. After considering a high probability of ibuprofen tolerance and obtaining informed consent from the patients, we performed a sequential allergy workup including in vitro tests, skin tests, and finally DPT in two of the patients, confirming ibuprofen tolerance. In conclusion, although generally contraindicated, DPT may be considered for some useful drugs after careful evaluation of the risk–benefit balance, preceded by a sequential study including in vitro and skin tests.

Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors

2004 ◽  
Vol 22 (8) ◽  
pp. 1389-1397 ◽  
Author(s):  
Bruno Sangro ◽  
Guillermo Mazzolini ◽  
Juan Ruiz ◽  
Maite Herraiz ◽  
Jorge Quiroga ◽  
...  
Keyword(s):  
Stable Disease ◽  
Adverse Reactions ◽  
Imaging Techniques ◽  
Primary Liver Cancer ◽  
Intratumoral Injection ◽  
Skin Tests ◽  
Interleukin 12 ◽  
Antitumor Effects ◽  
Tumor Biopsy ◽  
Viral Particles

Purpose To evaluate the feasibility and safety of intratumoral injection of an adenoviral vector encoding human interleukin-12 genes (Ad.IL-12) and secondarily, its biologic effect for the treatment of advanced digestive tumors. Patients and Methods Ad.IL-12 was administered in doses ranging from 2.5 × 1010 to 3 × 1012 viral particles, to seven cohorts of patients with advanced pancreatic, colorectal, or primary liver malignancies. Patients were thoroughly assessed for toxicity, and antitumor response was evaluated by imaging techniques, tumor biopsy, and hypersensitivity skin tests. Patients with stable disease and no serious adverse reactions were allowed to receive up to 3 monthly doses of Ad.IL-12. Results Twenty-one patients (nine with primary liver, five with colorectal, and seven with pancreatic cancers) received a total of 44 injections. Ad.IL-12 was well tolerated, and dose-limiting toxicity was not reached. Frequent but transient adverse reactions, including fever, malaise, sweating, and lymphopenia, seemed to be related to vector injection rather than to transgene expression. No cumulative toxicity was observed. In four of 10 assessable patients, a significant increase in tumor infiltration by effector immune cells was apparent. A partial objective remission of the injected tumor mass was observed in a patient with hepatocellular carcinoma. Stable disease was observed in 29% of patients, mainly those with primary liver cancer. Conclusion Intratumoral injection of up to 3 × 1012 viral particles of Ad.IL-12 to patients with advanced digestive malignancies is a feasible and well-tolerated procedure that exerts only mild antitumor effects.

Tamiflu Prophylaxis Tied to Adverse Reactions

2010 ◽  
Vol 44 (6) ◽  
pp. 10-11
Author(s):  
JENNIE SMITH
Keyword(s):  
Adverse Reactions

Ability of caregivers to read delayed hypersensitivity skin tests in children exposed to and infected by HIV*1

2000 ◽  
Vol 14 (2) ◽  
pp. 50-55
Author(s):  
FORTHEPEDIATRICPULMONARYANDCA ◽  
H COHEN ◽  
X CHEN ◽  
S SUNKLE ◽  
L DAVIS ◽  
...  
Keyword(s):  
Delayed Hypersensitivity ◽  
Skin Tests ◽  
Hypersensitivity Skin ◽  
Hiv 1

Sleep Drug Labels to Address Adverse Reactions

2007 ◽  
Vol 40 (7) ◽  
pp. 18-19
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Adverse Reactions
Sign in / Sign up

Export Citation Format

Share Document